Research programme: DCtag vaccines - PX Biosolutions

Drug Profile

Research programme: DCtag vaccines - PX Biosolutions

Alternative Names: DCtag™; OTAC-DCtag

Latest Information Update: 03 Apr 2013

Price : $50

At a glance

  • Originator Panvax
  • Developer Institut Pasteur; Panvax; PX Biosolutions
  • Class Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer; Malaria; Ovarian cancer
  • Research Asthma
  • Discontinued Viral infections

Most Recent Events

  • 02 Apr 2013 Discontinued - Preclinical for Malaria prevention in France (Parenteral)
  • 02 Apr 2013 Discontinued - Preclinical for Viral infections in Australia (Parenteral)
  • 02 Apr 2013 Preclinical trials in Ovarian cancer in Australia (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top